ArticleDrug design, development and therapy2025
Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anlotinib Plus Immune Checkpoint Inhibitors versus Chemotherapy in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer: A Real World, Exploratory Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the efficacy and safety of anlotinib combined with immune checkpoint inhibitors (ICIs) in patients with previously immunotherapy-treated extensive-stage small cell lung cancer (ES-SCLC). Methods: This retrospective study screened ES-SCLC patients who experienced failure after prior ICIs-based treatment and received anlotinib combined with ICIs therapy clinically. Anlotinib was administered at a standard dosage, ICIs regimens included PD-1 inhibitors (Tislelizumab, 200 mg; serplulimab, 4.5 mg/kg) and PD-L1 inhibitors. Efficacy and safety data during treatment were retrospectively collected, and patients were followed up regularly to obtain long-term survival data. Subgroup analysis was conducted to identify the differences in treatment outcomes in various baseline characteristics. Results: Of the 68 ES-SCLC patients included, no complete response, 22 patients achieved partial response, 28 had stable disease, 14 experienced disease progression and 4 patients were not available for efficacy. Objective response rate (ORR) was 32.4% (95% CI: 21.5-44.8%), and disease control rate (DCR) was 73.5% (95% CI: 61.4-83.5%). The median progression-free survival (PFS) was 5.6 months (95% CI: 3.87-7.33), the median duration of response (DoR) was 6.8 months (95% CI: 0.80-12.83). At the data cutoff date, the median follow-up duration was 12.5 months (range: 1.1-31.5 months), yielding a median overall survival (OS) of 13.2 months (95% CI: 7.09-19.31). Subgroup analysis highlighted that patients who were previously intolerant to immunotherapy had a longer OS (median OS: 15.5 vs 10.9 months, Conclusion: Anlotinib combined with ICIs demonstrated that immunotherapy rechallenge in previously ICIs-treated ES-SCLC was feasible and of clinical significance preliminarily. However, larger-scale clinical studies were required to validate these findings subsequently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.